z-logo
open-access-imgOpen Access
Increased rate of FEV1 decline in HIV patients despite effective treatment with HAART
Author(s) -
Gloria Sampériz,
Francisco Fanjul,
José Luis Valera,
Meritxell López,
Ángel Ríos,
María Peñaranda,
Antoni A Campins,
Melchor Riera,
Àlvar Agustí
Publication year - 2019
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0224510
Subject(s) - medicine , cohort , population , cohort study , viral load , human immunodeficiency virus (hiv) , risk factor , immunology , prospective cohort study , environmental health
Previous studies have reported that the rate of FEV1 decline over time is increased in HIV patients but the mechanisms underlying this observation are unclear. Since current HIV treatment with Highly Active Antiretroviral Therapy (HAART) results in very good immune-viral control, we hypothesized that HAART should normalize the elevated rate of FEV1 decline previously reported in HIV patients if it was somehow related to the immune alterations caused by HIV, particularly in never smokers or quitters, since smoking is a well established risk factor for accelerated FEV1 decline in the general population. Methods We explored this hypothesis in a prospectively recruited cohort of 188 HIV (smoker and non-smoker) patients treated with HAART in Palma de Mallorca (Spain) and followed-up for 6 years. The cross-sectional characteristics of this cohort have been published elsewhere. Results We found that: (1) HAART resulted in good immune-viral control; (2) the rate of FEV1 decline remained abnormally elevated, even in non-smokers and quitters; and, (3) alcohol abuse during follow-up was related to FEV1 decline in these patients. Discussion Despite adequate immune-viral control by HAART, lung function decline remains increased in most HIV patients, even in non-smokers and quitters. Alcohol abuse is a preventable risk factor to decrease the accelerated FEV1 decline in this population.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here